Chronic inflammation impairs insulin secretion and sensitivity. β-cell dedifferentiation has recently been proposed as a mechanism underlying β-cell failure in T2D. Yet the effect of inflammation on β-cell identity in T2D has not been studied. Therefore, we investigated whether pro-inflammatory cytokines induce β-cell dedifferentiation and whether anti-inflammatory treatments improve insulin secretion via β-cell redifferentiation. We observed that IL-1β, IL-6 and TNFα promote β-cell dedifferentiation in cultured human and mouse islets, with IL-1β being the most potent one of them. In particular, β-cell identity maintaining transcription factor Foxo1 was downregulated upon IL-1β exposure. In vivo, anti-IL-1β, anti-TNFα or NF-kB inhibiting sodium salicylate treatment improved insulin secretion of isolated islets. However, only TNFα antagonism partially prevented the loss of β-cell identity gene expression. Finally, the combination of IL-1β and TNFα antagonism improved insulin secretion of ex vivo isolated islets in a synergistic manner. Thus, while inflammation triggered β-cell dedifferentiation and dysfunction in vitro, this mechanism seems to be only partly responsible for the observed in vivo improvements in insulin secretion.
Pancreatic α cells may process proglucagon not only to glucagon but also to glucagon-like peptide-1 (GLP-1). However, the biological relevance of paracrine GLP-1 for β cell function remains unclear. We studied effects of locally derived insulin secretagogues on β cell function and glucose homeostasis using mice with α cell ablation and with α cell-specific GLP-1 deficiency. Normally, intestinal GLP-1 compensates for the lack of α cell-derived GLP-1. However, upon aging and metabolic stress, glucose tolerance is impaired. This was partly rescued with the DPP-4 inhibitor sitagliptin, but not with glucagon administration. In isolated islets from these mice, glucose-stimulated insulin secretion was heavily impaired and exogenous GLP-1 or glucagon rescued insulin secretion. These data highlight the importance of α cell-derived GLP-1 for glucose homeostasis during metabolic stress and may impact on the clinical use of systemic GLP-1 agonists versus stabilizing local α cell-derived GLP-1 by DPP-4 inhibitors in type 2 diabetes.
Pathological activation of the renin-angiotensin system (RAS) is associated with the metabolic syndrome, and the new onset of type 2 diabetes can be delayed by RAS inhibition. In animal models of type 2 diabetes, inhibition of the RAS improves insulin secretion. However, the direct effects of angiotensin II on islet function and underlying mechanisms independent of changes in blood pressure remain unclear. Here we show that exposure of human and mouse islets to angiotensin II induces interleukin (IL)-1–dependent expression of IL-6 and MCP-1, enhances β-cell apoptosis, and impairs mitochondrial function and insulin secretion. In vivo, mice fed a high-fat diet and treated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed defective glucose-stimulated insulin secretion and deteriorated glucose tolerance. Application of an anti–IL-1β antibody reduced the deleterious effects of angiotensin II on islet inflammation, restored insulin secretion, and improved glycemia. We conclude that angiotensin II leads to islet dysfunction via induction of inflammation and independent of vasoconstriction. Our findings reveal a novel role for the RAS and an additional rationale for the treatment of type 2 diabetic patients with an IL-1β antagonist.
Introduction: Glucose-dependent insulinotropic peptide (GIP) induces the cytokine interleukin (IL)-6 in adipocytes. IL-6 enhances insulin secretion from β-cells via L- and α-cell-derived GLP-1.Therefore we hypothesized that GIP regulates Glucagon-like peptide (GLP)-1 as well as glucose control via IL-6. Methods/Design: Basic research study on isolated human and mouse pancreatic islets and FACS-sorted human α-and β-cells that were treated with GIP in vitro. For in vivo studies, GIP effects on GLP-1 and insulin secretion as well as glucose homeostasis were evaluated in mouse models with pharmacologic and genetic ablation of IL-6. Results: GIP induced IL-6 in mouse and human pancreatic α-cells, leading to GLP-1 and insulin secretion in pancreatic islets. This effect was impaired in the absence of IL-6 and modulated by IL-1β which stimulated IL-6 but directly impaired GLP-1 production. Furthermore, inhibition of the sodium glucose transporter (SGLT)2 with dapagliflozin - enhanced GIP-induced GLP-1 release. In vivo, GIP increased plasma GLP-1 and insulin, and improved glucose tolerance, which was potentiated by lipopolysaccharide and strongly decreased in IL-6-deficient mice or in the presence of a blocking anti-IL-6 antibody. In diabetic mice, IL-1β and IL-6 were massively upregulated in isolated islets and GIP lost its effects on glycaemia control and GLP-1 induction. Conclusion: These data indicate that GIP induces GLP-1 and insulin via α-cell-derived IL-6, and that this effect is modulated by IL-1β and SGLT2 inhibtion. During diabetes, the prevailing inflammation may attenuate GIP effects. These findings further support the concept that the immune system plays an integral role in the regulation of metabolism in physiology and pathology.